Note: Descriptions are shown in the official language in which they were submitted.
1
DESCRIPTION
SOLID DISPERSION COMPRISING AMORPHOUS CILOSTAZOL
TECHNICAL FIELD
[0001]
The present invention relates to a solid dispersion
comprising amorphous cilostazol. In detail,
certain
embodiments relate to a solid dispersion comprising
cilostazol, and methacrylic acid copolymer S and/or
methacrylic acid copolymer L; and a pharmaceutical
composition comprising the solid dispersion.
In addition, certain embodiments also relate to
processes for preparing the solid dispersion, and
pharmaceutical compositions comprising the solid dispersion.
BACKGROUND ART
[0002]
Cilostazol is 6-[4-(1-
cyclonexy1-1H-tetrazol-5-
yl)butoxy]-3,4-dihydrocarbostyril as shown in the following
formula (1), which exhibits high inhibitory action for
platelet aggregation as well as inhibitory action for
phosphodiesterase, antiulcer activity, hypotensive action,
antiphlogistic action, etc. (Patent Reference 1) and
thereby is widely used in clinical use as a drug for
treating various ischemic symptoms caused by chronic
CA 2899389 2019-02-01
2
arterial occlusion such as ulcer, pain and coldness.
Cilostazol has been additionally approved as a medicament
having an indication which prevents relapse after treatment
of cerebral infarction (except cardiogenic cerebral
infarction).
The cilostazol tablets which are called Pletaal OD
tablets 50mg, Pletaal9 OD tablets 100m, and Pletaal powder 20 %
(OTSUKA PHARMACEUTICAL CO., LTD.) have already been on sale.
0
(I)
N
[0003]
Usually, cilostazol is orally administered twice a day
for an adult, but it has been desired to develop a new
sustained-release formulation of cilostazol which can be
absorbed in an intestinal track slowly but for a long time
even by one administration, because the main subject of the
drug is an elderly patient and it has been necessary to
reduce the development of side effects such as headache.
In addition, it has been also desired that a new
formulation of cilostazol which is little affected by a
food because cilostazol is susceptible to a food, for
example, the Cata,, and AUC of cilostazol administered after
CA 2899389 2019-02-01
3
meal are 2.3 and 1.4 times higher than those of fasting,
respectively.
For the purpose of developing such a sustained-release
formulation, there have been a variety of studies to
improve the release control and absorption of the poorly-
soluble drug, cilostazol in lower gastrointestinal tract
(Patent References 2 to 5).
[0004]
In order to improve the dissolution and absorption of
a poorly-soluble drug, in general, various means such as a
micronization (nano-particulation), a solubilization with
surfactants and oil, and also a solid dispersion method are
used.
The solid dispersion method is carried out by
; 15 dispersing a drug in an inert excipient, in many instances,
a drug exists in an amorphous state in the solid dispersion.
Thus, the solid dispersion method is often used as an
initial method to make an amorphous drug. As a process of
= preparing a solid dispersion, some methods are known, for
example, coprecipitating method, spray drying method, hot-
= melt method, and hot-melt extrusion method. For a skilled
person, the most-used method among them is a spray drying
method, but the other methods are sometimes used.
Patent Reference 6 discloses that a poorly-soluble
compound is dispersed in a water-insoluble ionic polymer
CA 2899389 2019-02-01
4
such as Eudragito so that a powder of a poorly-soluble
compound can be stabilized as an amorphous material.
Patent Reference 7 discloses a process of preparing a solid
dispersion comprising an amorphous compound by
coprecipitating or hot-melt extruding a very insoluble
imidazolidine derivative referred to as HEP with
hypromellose acetate succinate (HPMC-AS).
[0005]
In general, a compound in an amorphous state is
unstable toward water. In particular, a high crystallinity
compound in an amorphous state is unstable, which is known
to be easily crystallized by the absorption of moisture or
by being suspended with water. Thus, it is a big challenge
to inhibit the crystallization of a formulation containing
such an amorphous compound in a body, in case that the
formulation is, for example, a sustained release
formulation which stays in a gastrointestinal tract for
long time after oral administration.
[0006]
Cilostazol has an extremely low solubility in water,
and has a high crystallinity, thereby it was very difficult
to prepare a solid dispersion comprising a stable amorphous
cilostazol. Even though a solid dispersion comprising an
amorphous cilostazol can be successfully prepared through
some effort of process or formula, cilostazol will easily
CA 2899389 2019-02-01
5
crystallize when suspended in water. Thus, it was
very
difficult to apply an amorphous cilostazol to a sustained
release formulation which contacts to water for a long time.
PRIOR ART
[Patent Reference]
[0007]
[Patent Reference 1] JP 56(1981)-49378 A
[Patent Reference 2] JP 2011-520774 A
[Patent Reference 3] JP 2001-163769 A
[Patent Reference 4] WO 2007/072908
[Patent Reference 5] JP 2011-500511 A
[Patent Reference 6] JP 2000-095708 A
[Patent Reference 7] JP 2010-526848 A
SUMMARY
[0008]
The purpose of certain embodiments is to provide a
solid dispersion comprising cilostazol, wherein cilostazol
having an extremely low solubility in water and a high
crystallinity is retained in an amorphous state in a
gastrointestinal tract for a certain period after oral
administration.
CA 2899389 2019-02-01
6
[0009]
The present inventors have intensively studied and
found that it is possible to prepare a solid dispersion
(extrudate) comprising cilostazol which can be retained in
a stable amorphous state in an aqueous suspension, by hot-
melting or hot-melt extruding a mixture of cilostazol and
methacrylic acid copolymer S and/or methacrylic acid
copolymer L which is an enteric polymer in a certain ratio.
Based upon the new findings, the present invention has been
completed.
[0010]
Certain embodiments provide
pharmaceutical
compositions and use thereof as shown in the following [1]
to [10].
[1] A solid dispersion comprising (i) cilostazol and
(ii) methacrylic acid copolymer S and/or methacrylic acid
copolymer L, wherein cilostazol is dispersed in an
amorphous state in the methacrylic acid copolymer.
[0011]
[2] The solid dispersion of [1] which is prepared by
hot-melt or hot-melt extrusion.
[0012]
[3] The solid dispersion of [2] which is prepared by
hot-melt extrusion.
CA 2899389 2019-02-01
7
[0013]
[4] The solid dispersion of any one of [1] to [3]
wherein the ratio of (i) cilostazol and (ii) methacrylic
acid copolymer S and/or methacrylic acid copolymer L is 1 :
0.5 to 1 : 3 by weight.
[0014]
[5] The solid dispersion of any one of [1] to [3]
wherein the ratio of (i) cilostazol and (ii) methacrylic
acid copolymer S and/or methacrylic acid copolymer L is 1 :
1 to 1 : 3 by weight.
[0015]
[6] The solid dispersion of any one of [1] to [5]
wherein (ii) methacrylic acid copolymer S and/or
methacrylic acid copolymer L is methacrylic acid copolymer
S.
[0016]
[7] The solid dispersion of any one of [1] to [5]
wherein (ii) methacrylic acid copolymer S and/or
methacrylic acid copolymer L is methacrylic acid copolymer
L.
[0017]
[8] A pharmaceutical composition comprising the solid
dispersion of any one of [1] to [7].
CA 2899389 2019-02-01
8
[0018]
[9] An oral formulation comprising the pharmaceutical
composition of [8].
[0019]
[10] A process of preparing a solid dispersion which
comprises
hot-melting or hot-melt extruding (i) cilostazol and
(ii) methacrylic acid copolymer S and/or methacrylic acid
copolymer L, and then
cooling and milling the extruded product.
[Effect of the Invention]
[0020]
Cilostazol in the present solid dispersion can be
stably retained in an amorphous state, and even when the
solid dispersion is suspended in water, all or most of the
contained cilostazol can be retained in an amorphous state
at least for 24 hours. Thereby, it is expected that
cilostazol in the present solid dispersion can be retained
in an amorphous state in a gastrointestinal tract for a
long time after oral administration.
In addition, the present solid dispersion has a very
strong acid-resistance since it comprises methacrylic acid
copolymer S and/or methacrylic acid copolymer L which is an
enteric polymer. This property enables the solid
dispersion not to be dissolved in the stomach, but to be
CA 2899389 2019-02-01
9
dissolved in lower section of the small intestine where is
in a high pH range simultaneously to elute out cilostazol
via the behavior that methacrylic acid copolymer S and/or
methacrylic acid copolymer L are rapidly dissolved there.
As a result, the present solid dispersion is expected to
make cilostazol dissolved in a lower section of a
gastrointestinal tract and improve the absorption of
cilostazol.
BRIEF DESCRIPTION OF DRAWINGS
[0021]
Fig. 1 represents an analytical result in powder X-ray
diffraction that the stability in an aqueous suspension of
the solid dispersion prepared by hot-melt extrusion of
cilostazol and methacrylic acid copolymer S (Eudragit S
100) was evaluated. The top pattern of the powder X-ray
diffraction shows a result in powder X-ray diffraction with
a jet-milled crystalline cilostazol, the second top pattern
of the powder X-ray diffraction shows a result in powder X-
ray diffraction with methacrylic acid copolymer S
(Eudragito S 100), the third top pattern of the powder X-
ray diffraction shows a result in powder X-ray diffraction
with the solid dispersion (<150 pm) prepared in Example 3
in which the ratio of cilostazol and methacrylic acid
copolymer S is 1 : 2, the fourth top pattern of the powder
CA 2899389 2019-02-01
10
X-ray diffraction shows a result in powder X-ray
diffraction with the solid dispersion (<150 pm) of Example
3 which was stored as an aqueous suspension at 37 C for 1
hour after preparing the suspension, the fifth top pattern
of the powder X-ray diffraction shows a result in powder X-
ray diffraction with the solid dispersion (<150 pm) of
Example 3 which was stored as an aqueous suspension at 37 C
for 5 hours after preparing the suspension, and the bottom
pattern of the powder X-ray diffraction shows a result in
powder X-ray diffraction with the solid dispersion
(<150 pm) of Example 3 which was stored as an aqueous
suspension at 37 C for 24 hours after preparing the
suspension.
Fig. 2 represents an analytical result in powder X-ray
diffraction that the stability in an aqueous suspension of
the solid dispersion prepared by hot-melt extrusion of
cilostazol and methacrylic acid copolymer L (Eudragit L
100) was evaluated. The top pattern of the powder X-ray
diffraction shows a result in powder X-ray diffraction with
a jet-milled crystalline cilostazol, the second top pattern
of the powder X-ray diffraction shows a result in powder X-
ray diffraction with methacrylic acid copolymer L
(Eudragito L 100), the third top pattern of the powder X-
ray diffraction shows a result in powder X-ray diffraction
with the solid dispersion (<150 pm) prepared in Example 5
CA 2899389 2019-02-01
11
in which the ratio of cilostazol and methacrylic acid
copolymer L is 1 : 2, the fourth top pattern of the powder
X-ray diffraction shows a result in powder X-ray
diffraction with the solid dispersion (<150 pm) of Example
5 which was stored as an aqueous suspension at 37 C for 1
hour after preparing the suspension, the fifth top pattern
of the powder X-ray diffraction shows a result in powder X-
ray diffraction with the solid dispersion (<150 pm) of
Example 5 which was stored as an aqueous suspension at 37 C
for 5 hours after preparing the suspension, and the bottom
pattern of the powder X-ray diffraction shows a result in
powder X-ray diffraction with the solid dispersion
(<150 pm) of Example 5 which was stored as an aqueous
suspension at 37 C for 24 hours after preparing the
suspension.
Fig. 3 represents an analytical result in powder X-ray
diffraction that the stability in an aqueous suspension of
the solid dispersion prepared by hot-melt extrusion of
cilostazol and hydroxypropyl methylcellulose acetate
succinate (Shin-Etsu AQOAT, AS-HF) was evaluated. The top
pattern of the powder X-ray diffraction shows a result in
powder X-ray diffraction with a jet-milled crystalline
cilostazol, the second top pattern of the powder X-ray
diffraction shows a result in powder X-ray diffraction with
hydroxypropyl methylcellulose acetate succinate (Shin-Etsu
CA 2899389 2019-02-01
12
AQOAT, AS-HF), the third top pattern of the powder X-ray
diffraction shows a result in powder X-ray diffraction with
the solid dispersion (<150 pm) prepared in Comparative
Example 3 in which the ratio of cilostazol and
hydroxypropyl methylcellulose acetate succinate (Shin-Etsu
AQOAT, AS-HF) is 1 : 2, the fourth top pattern of the
powder X-ray diffraction shows a result in powder X-ray
diffraction with the solid dispersion (<150 pm) of
Comparative Example 3 which was stored as an aqueous
suspension at 37 C for 1 hour after preparing the
suspension, the fifth top pattern of the powder X-ray
diffraction shows a result in powder X-ray diffraction with
the solid dispersion (<150 pm) of Comparative Example 3
which was stored as an aqueous suspension at 37 C for 5
hours after preparing the suspension, and the bottom
pattern of the powder X-ray diffraction shows a result in
powder X-ray diffraction with the solid dispersion
(<150 pm) of Comparative Example 3 which was stored as an
= aqueous suspension at 37 C for 24 hours after preparing the
suspension.
Fig. 4 represents dissolution patterns in the solid
dispersion (<150 pm) of Example 3 under several pH
conditions.
CA 2899389 2019-02-01
13
Fig. 5 represents dissolution patterns in each solid
dispersion (<150 pm) of Examples 1, 2 and 3, and a jet-
milled crystalline cilostazol in McIlvaine buffer (pH 7.4).
Fig. 6 represents dissolution patterns in the solid
dispersions (<150 pm and 250-500 pm) of Example 3, and a
jet-milled crystalline cilostazol in McIlvaine buffer (pH
7.4).
Fig. 7 represents a graph showing the profile in
plasma concentration of cilostazol when each solid
dispersion of Examples 2 and 3, and Comparative Example 3,
and Pletaal tablet were administered to minipigs.
Fig. 8 represents a graph showing the profile in serum
concentration of cilostazol when the tablet of Formulation
Example 6 and Pletaal tablet were administered to dogs.
Fig. 9 represents a result in the dissolution test
with the tablet of Formulation Examples 6, 7 and 8, and
Pletaal tablet in a phosphate buffer (pH 6.8) containing
cetyltrimethylammonium bromide.
DESCRIPTION OF EMBODIMENTS
[0022]
Cilostazol can be prepared, for example, by the
process disclosed in JP-56-49378 A.
CA 2899389 2019-02-01
14
[0023]
As methacrylic acid copolymer S and methacrylic acid
copolymer L used herein, for example, Eudragito S 100 and
Eudragit L 100 provided by EVONIK Industries are well
known respectively, both of which have an anionic copolymer
structure composed of methacrylic acid and methyl
methacrylate. Methacrylic acid copolymer S is composed of
the acid and the ester in a ratio of about 1 : 2, and
methacrylic acid copolymer L is composed of the acid and
the ester in a ratio of about 1 : 1. The average molecular
weight of the both is about 123,000. Methacrylic
acid
copolymer S has a property to be dissolved at pH range of 7
or higher, and methacrylic acid copolymer L has a property
to be dissolved at pH range of 6 or higher. Through the
properties of the pH dependency, the both are known as an
enteric coating agent.
[0024]
The term "methacrylic acid copolymer S and/or
methacrylic acid copolymer L" in the present invention mean
that the both can be contained or either of them can be
contained. Both ingredients can be contained in any ratio
according to various embodiments.
[0025]
Regarding the solid dispersion of the present
invention, the weight ratio of (i) cilostazol, and
CA 2899389 2019-02-01
15
(ii) methacrylic acid copolymer S and/or methacrylic acid
copolymer L is not limited as long as the ratio is in about
1 : 0.1 to about 1 : 10, but generally about 1 : 0.5 or
more, preferably about 1 : 1 or more, more preferably about
1 : 1 to about 1 : 5, even more preferably about 1 : 1 to
about 1 : 3, and most preferably about 1 : 2.
[0026]
The process of preparing the present solid dispersion
includes hot-melt and hot-melt extrusion. In detail, these
methods are characterized by uniformly mixing a drug, a
polymer and optional excipients; melting the mixture by
heating; and then cooling it. In these
methods, a
conventional method and device such as a mixer and kneader
equipped with heat source can be used.
[0027]
In the hot-melt or the hot-melt extrusion, an extruder
equipped with a screw in the barrel (cylinder) (e.g.,
single screw exLruder, twin screw extruder, etc.) can be
used. Among these
extruders, a twin screw extruder has
recently become mainstream.
An extruder is composed of five main parts, i.e.,
hopper (input structure), motor (controlling the rotation
of screw), screw (primary source for shearing a material
and moving it), barrel (housing a screw and controlling the
CA 2899389 2019-02-01
16
temperature), and die (outlet) (controlling the shape and
size of extrudate).
Therein, a drug, a polymer, and optional excipients
are thrown into the machine via the hopper, in which the
temperature of the hot-melt is suitably retained, and then
the solid mixture is melted by the rotation of the screw to
be kneaded uniformly. Or, it is possible to preliminarily
mix the ingredients before throwing them into the machine,
as appropriate.
[0028]
The polymer used in the hot-melt extrusion is not
limited as long as it is a natural or artificial polymer
compound to be generally used as a material for
pharmaceutical formulation and additionally the function of
the polymer does not disappear when discharged from the die
in a twin screw extruder, which includes a pH dependent
polymer, a pH independent polymer, and a water-soluble
polymer. In the present invention, methacrylic acid
copolymer S and/or methacrylic acid copolymer L are used as
such polymer.
[0029]
In the hot-melt extrusion, other excipients besides
the above-mentioned polymer may be also used herein. Such
excipients are not limited as long as they are what are
generally used as a material for pharmaceutical formulation
CA 2899389 2019-02-01
17
and additionally they do not damage the function of the
present solid dispersion.
[0030]
The setting condition in the process of the present
invention such as pressure, temperature, speed of supplying
material powder, diameter of die, shape of screw, and
rotary speed of screw depends on the types of the used drug,
polymer and extruder.
It is important to combine each
suitable condition to keep the process temperature under
the decomposition temperatures of the drug and the polymer,
and it is necessary to vary each condition in response to
the character of the desired product.
In the hot-melt method or the hot-melt extrusion
method, generally it is necessary to heat to make the
process temperature over the glass-transition temperature
of the drug and the polymer. On the other hand, from the
viewpoint of the stability of the drug, polymer and
excipients for decomposition or denaturation, the heat
temperature needs to be set suitably, in general 200 C or
lower, preferably about 180 C or lower is chosen.
[0031)
The very preferred polymer in the present invention
includes methacrylic acid copolymer S (Eudragit S 100) and
methacrylic acid copolymer L (Eudragit L 100), whose
1 25 glass-transition temperatures are very high, about 160 C
CA 2899389 2019-02-01
18
and about 150 C, respectively. In order to
hot-melt
extrude these polymers, it is necessary to heat them over
their glass-transition temperatures, but such high
temperatures can cause the decomposition of the polymers
themselves. The inventors actually studied the preparation
of hot-melt extrusion products using methacrylic acid
copolymer S and methacrylic acid copolymer L, but it was
very difficult to extrude the methacrylic acid copolymer S
or methacrylic acid copolymer L alone. Thus, it was
confirmed that methacrylic acid copolymer S and methacrylic
acid copolymer L are not suitable for the extruding by hot-
melt at all. Thus, many
prior references suggest the
possibility to use methacrylic acid copolymer S and
methacrylic acid copolymer L in hot-melt extrusion (hot-
melt and extrusion), but there have not been any actually
successful examples of such preparation in the past.
[0032]
The melting point of cilostazol contained in the
present solid dispersion is 160 C to 180 C. In order to
make a high crystallinity cilostazol in an amorphous state,
it is necessary to make cilostazol melted completely.
[0033]
The present inventors have found that it is possible
to stably prepare a solid dispersion comprising amorphous
cilostazol by hot-melt extruding cilostazol together with
CA 2899389 2019-02-01
19
methacrylic acid copolymer S and/or methacrylic acid
copolymer L which are difficult to be extruded alone,
without decomposing the polymers. And also,
the present
inventors have found that all or most of cilostazol in the
prepared solid dispersion can be retained in an amorphous
state at least for 24 hours even when the solid dispersion
is suspended in water.
[0034]
The solid dispersion of the present invention is
preferably prepared as follows:
Preliminarily, cilostazol and methacrylic acid
copolymer S (Eudragit S 100) and/or methacrylic acid
copolymer L (Eudragit L 100) are mixed.
The mixed powder is supplied into a twin screw
extruder in a constant supply speed of 10 to 200 g/min, and
then it is treated in the machine at a screw speed of 50 to
300 rpm, and at a temperature of 50 C to 300 C.
[0035]
When the solid dispersion prepared herein is milled
with an appropriate pulverizer, it is possible to easily
prepare a particle of the solid dispersion having any
desired particle size. The particle can be directly used
as a powder, fine granule, or granule preparation; or
further the solid dispersion of the present invention (or a
particle of the solid dispersion) can be also processed,
CA 2899389 2019-02-01
20
optionally adding an ingredient for pharmaceutical
preparation (excipient), to a pharmaceutical composition
comprising the solid dispersion. The
ingredient for
pharmaceutical preparation to be added here includes, for
example, excipients, disintegrating agents, binders,
fluidizer, lubricants, preservatives, stabilizing agent,
isotonic agents, solubilizers, sweeteners, flavors,
preservatives, dispersants, and pH adjusters. The
excipient to be contained in the solid dispersion also
includes the same.
[0036]
The oral formulation of the present invention includes,
for example, a solid formulation such as a tablet, a
capsule, a powder, and a granule.
EXAMPLE
[0037]
Hereinafter, the present invention is illustrated by
the following examples, comparative examples, formulation
examples and tests, but should not be construed to be
limited thereto, and it is possible to vary each condition
unless the variation is beyond the range of the present
invention.
CA 2899389 2019-02-01
21
[0038]
(Preparation of Solid Dispersion by Hot-melt Extrusion)
Example 1. Solid dispersion (methacrylic acid copolymer S,
0.5 parts)
500 g of cilostazol (hammer-milled powder, Otsuka
Pharmaceutical Co., Ltd.) and 250 g of methacrylic acid
copolymer S (commercial name: Eudragit S 100, Evonik Japan
Co., Ltd.) were mixed in a polyethylene bag for several
minutes.
The mixed powder was shaped with a twin screw extruder
(KEX-25, KURIMOTO, LTD.) having dies whose gauge was 2 mmO,
in which the barrel temperature in its kneading part was
set at 100 to 180 C and the extrusion rate was set at 100
to 150 rpm, to give a stick-shaped extrudate (solid
dispersion).
The extrudate was cooled at room temperature,
micronized with a pulverizer (Power Mill P-3S Model, Dalton
Co., Ltd.) and another pulverizer (Fine Impact Mill 100 uPZ,
Hosokawa Micron Corporation) and then screened to give a
solid dispersion having a certain particle size
distribution.
CA 2899389 2019-02-01
22
[0039]
Example 2. Solid dispersion (methacrylic acid copolymer S,
1 part)
500 g of cilostazol (hammer-milled powder, Otsuka
Pharmaceutical Co., Ltd.) and 500 g of methacrylic acid
copolymer S (commercial name: Eudragit S 100, Evonik Japan
Co., Ltd.) were mixed in a polyethylene bag for several
minutes.
The mixed powder was shaped with a twin screw extruder
(KEX-25, KURIMOTO, LTD.) having dies whose gauge was 2 mm,
in which the barrel temperature in its kneading part was
set at 100 to 180 C and the extrusion rate was set at 100
to 150 rpm, to give a stick-shaped extrudate (solid
dispersion).
The extrudate was cooled at room temperature,
micronized with a pulverizer (Power Mill P-3S Model, Dalton
Co., Ltd.) and another pulverizer (Fine Impact Mill 100 UPZ,
Hosokawa Micron Corporation) and then screened to give a
solid dispersion having a certain particle size
distribution.
[0040]
Example 3. Solid dispersion (methacrylic acid copolymer S,
2 parts)
500 g of cilostazol (hammer-milled powder, Otsuka
Pharmaceutical Co., Ltd.) and 1000 g of methacrylic acid
CA 2899389 2019-02-01
23
copolymer S (commercial name: Eudragit0 S 100, Evonik Japan
Co., Ltd.) were mixed in a polyethylene bag for several
minutes.
The mixed powder was shaped with a twin screw extruder
(KEX-25, KURIMOTO, LTD.) having dies whose gauge was 2 mm',
in which the barrel temperature in its kneading part was
set at 100 to 180 C and the extrusion rate was set at 100
to 150 rpm, to give a stick-shaped extrudate (solid
dispersion).
The extrudate was cooled at room temperature,
micronized with a pulverizer (Power Mill P-3S Model, Dalton
Co., Ltd.) and another pulverizer (Fine Impact Mill 100 UPZ,
Hosokawa Micron Corporation) and then screened to give a
solid dispersion having a certain particle size
distribution.
[0041]
Example 4. Solid dispersion (methacrylic acid copolymer S,
3 parts)
500 g of cilostazol (hammer-milled powder, Otsuka
Pharmaceutical Co., Ltd.) and 1500 g of methacrylic acid
copolymer S (commercial name: Eudragito S 100, Evonik Japan
Co., Ltd.) were mixed in a polyethylene bag for several
minutes.
The mixed powder was shaped with a twin screw extruder
(KEX-25, KURIMOTO, LTD.) having dies whose gauge was 2 mm,
CA 2899389 2019-02-01
24
in which the barrel temperature in its kneading part was
set at 100 to 200 C and the extrusion rate was set at 100
to 150 rpm, to give a stick-shaped extrudate (solid
dispersion).
The extrudate was cooled at room temperature,
micronized with a pulverizer (Power Mill P-3S Model, Dalton
Co., Ltd.) and another pulverizer (Fine Impact Mill 100 UPZ,
Hosokawa Micron Corporation) and then screened to give a
solid dispersion having a certain particle size
distribution.
[0042]
Example 5. Solid dispersion (methacrylic acid copolymer L,
2 parts)
500 g of cilostazol (hammer-milled powder, Otsuka
Pharmaceutical Co., Ltd.) and 1000 g of methacrylic acid
copolymer L (commercial name: Eudragit L 100, Evonik Japan
Co., Ltd.) were mixed in a polyethylene bag for several
minutes.
The mixed powder was shaped with a twin screw extruder
(KEX-25, KURIMOTO, LTD.) having dies whose gauge was 2 mm,
in which the barrel temperature in its kneading part was
set at 100 to 190 C and the extrusion rate was set at 100
to 150 rpm, to give a stick-shaped extrudate (solid
dispersion).
CA 2899389 2019-02-01
25
The extrudate was cooled at room temperature,
micronized with a pulverizer (Power Mill P-3S Model, Dalton
Co., Ltd.) and another pulverizer (Fine Impact Mill 100 0PZ,
Hosokawa Micron Corporation) and then screened to give a
solid dispersion having a certain particle size
distribution.
(00433
Comparative Example 1. Solid dispersion (methacrylic acid
copolymer S, 1 part; polyethylene glycol, 0.2 parts)
500 g of cilostazol (hammer-milled powder, Otsuka
Pharmaceutical Co., Ltd.), 500 g of methacrylic acid
copolymer S (commercial name: Eudragito S 100, Evonik Japan
Co., Ltd.) and 100 g of polyethylene glycol (macrogol 6000,
Sanyo Chemical Industries, Ltd.) were mixed in a
polyethylene bag for several minutes.
The mixed powder was shaped with a twin screw extruder
(KEX-25, KURIMOTO, LTD.) having dies whose gauge was 2 mmO,
in which the barrel temperature in its kneading part was
set at 100 to 170 C and the extrusion rate was set at 100
to 150 rpm, to give a stick-shaped extrudate (solid
dispersion).
The extrudate was cooled at room temperature,
micronized with a pulverizer (Power Mill P-3S Model, Dalton
Co., Ltd.) and another pulverizer (Fine Impact Mill 100 UPZ,
Hosokawa Micron Corporation) and then screened to give a
CA 2899389 2019-02-01
26
solid dispersion having a certain particle size
distribution.
[0044]
Comparative Example 2. Solid dispersion (hydroxypropyl
methylcellulose acetate succinate, 1 part)
500 g of cilostazol (hammer-milled powder, Otsuka
Pharmaceutical Co., Ltd.) and 500 g of hydroxypropyl
methylcellulose acetate succinate (commercial name: Shin-
Etsu AQOAT0, Type: AS-HF, Shin-Etsu Chemical Co., Ltd.)
were mixed in a polyethylene bag for several minutes.
The mixed powder was shaped with a twin screw extruder
(KEX-25, KURIMOTO, LTD.) having dies whose gauge was 2 mmt.,
in which the barrel temperature in its kneading part was
set at 100 to 160 C and the extrusion rare was set at 100
to 150 rpm, to give a stick-shaped extrudate (solid
dispersion).
The extrudate was cooled at room temperature,
micronized with a pulverizer (Power Mill P-3S Model, Dalton
Co., Ltd.) and another pulverizer (Fine Impact Mill 100 UPZ,
Hosokawa Micron Corporation) and then screened to give a
solid dispersion having a certain particle size
distribution.
CA 2899389 2019-02-01
27
[0045]
Comparative Example 3. Solid dispersion (hydroxypropyl
methylcellulose acetate succinate, 2 parts)
500 g of cilostazol (hammer-milled powder, Otsuka
Pharmaceutical Co., Ltd.) and 1000 g of hydroxypropyl
methylcellulose acetate succinate (commercial name: Shin-
Etsu AQOATD, Type:AS-HF, Shin-Etsu Chemical Co., Ltd.) were
mixed in a polyethylene bag for several minutes.
The mixed powder was shaped with a twin screw extruder
(KEX-25, KURIMOTO, LTD.) having dies whose gauge was 2 mm(1),
in which the barrel temperature in its kneading part was
set at 100 to 150 C and the extrusion rate was set at 100
to 150 rpm, to give a stick-shaped extrudate (solid
dispersion).
The extrudate was cooled at room temperature,
micronized with a pulverizer (Power Mill P-3S Model, Dalton
Co.,Ltd.) and another pulverizer (Fine Impact Mill 100 UPZ,
Hosokawa Micron Corporation) and then screened to give a
solid dispersion having a certain particle size
distribution.
CA 2899389 2019-02-01
28
[0046]
(Preparation of Solid Dispersion by Spray Drying)
Comparative Example 4. Solid dispersion (hypromellose
phthalate, 2 parts)
5 g of cilostazol (hammer-milled powder, Otsuka
Pharmaceutical Co., Ltd.) and 10 g of hypromellose
phthalate (commercial name: HPMCP , Grade: HP-50, Shin-Etsu
Chemical Co., Ltd.) were dissolved in 300 g of a mixture of
dichloromethane and ethanol (dichloromethane/ethanol =
8/2 (w/w)). The solution was spray-
dried with a spray
dryer (GS310, Yamato Scientific Co., Ltd.) to give a solid
dispersion. The spray
drying was carried out under the
conditions of the inlet temperature: 70 C, the spray speed:
g/min, and the air volume: 0.4 to 0.5 m3/min. In order
15 to remove the residual solvent, the resulting solid
dispersion was further dried with a vacuum dryer (LCV-232,
TABAI ESPEC CORP.) at 50 C for 24 hours to give a solid
dispersion as a test sample.
[0047]
20 Comparative Example 5. Solid dispersion (hydroxypropyl
methylcellulose acetate succinate, 2 parts)
5 g of cilostazol (hammer-milled powder, Otsuka
Pharmaceutical Co., Ltd.) and 10 g of hydroxypropyl
methylcellulose acetate succinate (commercial name: Shin-
Etsu AQOAT0, grade: AS-HF, Shin-Etsu Chemical Co., Ltd.)
CA 2899389 2019-02-01
29
were dissolved in 300 g of a mixture of dichloromethane and
ethanol (dichloromethane/ethanol = 8/2 (w/w)). The
solution was spray-dried with a spray dryer (GS310, Yamato
Scientific Co., Ltd.) to give a solid dispersion. The
spray drying was carried out under the conditions of the
inlet temperature: 70 C, the spray speed: 20 g/min, and the
air volume: 0.4 to 0.5 m3/min. In order to
remove the
residual solvent, the resulting solid dispersion was
further dried with a vacuum dryer (LCV-232, TABAI ESPEC
CORP.) at 50 C for 24 hours to give a solid dispersion as a
test sample.
[0048]
Comparative Example 6. Solid dispersion (methacrylic acid
copolymer S, 2 parts)
5 g of cilostazol (hammer-milled powder, Otsuka
Pharmaceutical Co., Ltd.) and 10 g of methacrylic acid
copolymer S (commercial name: Eudragit S 100, Evonik Japan
Co., Ltd.) were dissolved in 800 g of a mixture of
dichloromethane and ethanol (dichloromethane/ethanol =
8/2 (w/w)). The solution was spray-
dried with a spray
dryer (GS310, Yamato Scientific Co., Ltd.) to give a solid
dispersion. The spray
drying was carried out under the
condition of the inlet temperature: 70 C, the spray speed:
20 g/min, and the air volume: 0.4 to 0.5 m3/min. In order
to remove the residual solvent, the resulting solid
CA 2899389 2019-02-01
30
dispersion was further dried with a vacuum dryer (LCV-232,
TABAI ESPEC CORP.) at 50 C for 24 hours to give a solid
dispersion as a test sample.
[0049]
Comparative Example 7. Solid dispersion
(hydroxypropylcellulose, 2 parts)
5 g of cilostazol (hammer-milled powder, Otsuka
Pharmaceutical Co., Ltd.) and 10 g of
hydroxypropylcellulose (commercial name: NISSO0 HPC, grade:
SL, NIPPON SODA CO., LTD.) were dissolved in 300 g of a
mixture of dichloromethane and ethanol
(dichloromethane/ethanol = 8/2 (w/w)). The
solution was
spray-dried with a spray dryer (GS310, Yamato Scientific
Co., Ltd.) to give a solid dispersion. The spray
drying
was carried out under the conditions of the inlet
temperature: 70 C, the spray speed: 20 g/min, and the air
volume: 0.4 to 0.5 m3/min. In order to remove the residual
solvent, the resulting solid dispersion was further dried
with a vacuum dryer (LCV-232, TABAI ESPEC CORP.) at 50 C
for 24 hours to give a solid dispersion as a test sample.
[0050]
Comparative Example 8. Solid dispersion (hypromellose, 2
parts)
5 g of cilostazol (hammer-milled powder, Otsuka
Pharmaceutical Co., Ltd.) and 10 g of hypromenose
CA 2899389 2019-02-01
31
(commercial name: TC-50, grade: TC-5E, Shin-Etsu Chemical
Co., Ltd.) were dissolved in 300 g of a mixture of
dichloromethane and ethanol (dichloromethane/ethanol =
8/2 (w/w)). The
solution was spray-dried with a spray
dryer (GS310, Yamato Scientific Co., Ltd.) to give a solid
dispersion. The spray
drying was carried out under the
conditions of the inlet temperature: 70 C, the spray speed:
20 g/min, and the air volume: 0.4 to 0.5 m3/min. In order
to remove the residual solvent, the resulting solid
dispersion was further dried with a vacuum dryer (LCV-232,
TABAI ESPEC CORP.) at 50 C for 24 hours to give a solid
dispersion as a test sample.
[0051]
Comparative Example 9. Solid dispersion
(polyvinylpyrrolidone K25, 2 parts)
5 g of cilostazol (hammer-milled powder, Otsuka
Pharmaceutical Co., Ltd.) and 10 g of polyvinylpyrrolidone
K25 (commercial name: Kollidono 25, BASF JAPAN LTD.) were
dissolved in 300 g of a mixture of dichloromethane and
ethanol (dichloromethane/ethanol = 8/2 (w/w)). The
solution was spray-dried with a spray dryer (GS310, Yamato
Scientific Co., Ltd.) to give a solid dispersion. The
spray drying was carried out under the conditions of the
inlet temperature: 70 C, the spray speed: 20 g/min, and the
air volume: 0.4 to 0.5 m3/min. In order to remove
the
CA 2899389 2019-02-01
32
residual solvent, the resulting solid dispersion was
further dried with a vacuum dryer (LCV-232, TABAI ESPEC
CORP.) at 50 C for 24 hours to give a solid dispersion as a
test sample.
[0052]
Using the solid dispersion prepared by a suitable
process, various pharmaceutical formulations such as a
tablet, a granule and a capsule can be prepared by means of
a conventional known technique. The
pharmaceutical
formulations can be administered via any suitable routes.
In the following, some solid dispersions were suspended in
water, and the change of crystalline state of cilostazol in
the suspensions was evaluated with a powder X-ray
diffractometer to estimate the intravital change of
crystalline state of cilostazol after administering the
formulation.
[0053]
Test 1
With regard to each of the solid dispersions prepared
in Examples 1 to 5, Comparative Examples 1 to 3, and
Comparative Examples 4 to 9, the change of crystalline
state of cilostazol was evaluated with a powder X-ray
diffractometer, between each solid dispersion shortly after
prepared and the one after suspended in water.
CA 2899389 2019-02-01
33
[0054]
The measurement conditions of powder X-ray diffraction
are shown below.
Measuring set: X' Pert PRO MPD (Spectris Co., Ltd.)
Optical system: parafocusing optics (transmission method)
Goniometer radius: 240 mm
Tube voltage, Tube current: 45 kV, 40 mA
Entrance slit: Soller Slit, Soller 0.04 rad
Divergence Slit 1/2 deg
Light-receiving slit: Soller Slit, Large Soller 0.04 rad
Antiscatter slit 5.5 mm
Measurement range: 20 3 to 40 deg
Scan rate: 1.11 deg/s
Sampling interval: 0.02 deg/step
Wobbled scan: Step number 5, Step size 0.02 deg
[0055]
Each of the micronized particles (<150 pm) prepared in
the above Examples 1 to 5, and Comparative Examples 1 to 3
was measured about their powder X-ray diffraction patterns.
Separately, about 2 g of each micronized particle
prepared in Examples 1 to 5, and Comparative Examples 1 to
3 which was passed with 150 pm mesh was put in a sample
tube. To the sample tube was added 30 ml of purified water
to prepare a suspension, and the suspension was shaken at
37 C for 1 hour, 5 hours and 24 hours. After shaking, the
CA 2899389 2019-02-01
34
suspended sample was got out of the sample tube, the excess
water was removed from the suspended sample, and then the
powder X-ray diffraction pattern thereof was measured to
evaluate the change of the crystalline property.
[0056]
The results of the measure are shown in Table 1 below.
And, the analytical results about the powder X-ray
diffraction of the solid dispersion (<150 pm) prepared in
Example 3, solid dispersion (<150 pm) prepared in Example 5,
and the solid dispersion (<150 pm) prepared in Comparative
Example 3 are shown in Fig. 1 to 3.
In each solid dispersion shortly after prepared by the
hot-melt extrusion, cilostazol existed in an amorphous
state; but the solid dispersion comprising cilostazol and
hydroxypropyl methylcellulose acetate succinate got quickly
crystallized only in an hour after suspended in water. On
the other hand, the solid dispersion comprising one or more
parts by weight of methacrylic acid copolymer s or
methacrylic acid copolymer L per one part by weight of
cilostazol was retained in an amorphous state even 24 hours
after suspended in water. In addition,
when methacrylic
acid copolymer S was used in the solid dispersion, but
polyethylene glycol was added thereto, then the
crystallization of the solid dispersion was accelerated.
This result is thought to be caused by the tendency that a
CA 2899389 2019-02-01
35
plasticizer or a high water-absorbing excipient such as
polyethylene glycol promotes the crystallization. Thus,
the solid dispersion of the present invention should not
comprise such ingredient.
[Table 1]
Formulae Shortly Temperature (37 C)
after 1 hr 5 hr 24 hr
preparation
Example 1 cilostazol/ amorphous crystal crystall-
crystall-
methacrylic acid peak ized ized
copolymer S exists
= 1/0.5
Example 2 cilostazol/ amorphous still still still
methacrylic acid amorphous amorphous amorphous
copolymer S
= 1/1
Example 3 cilostazol/ amorphous still still still
methacrylic acid amorphous amorphous amorphous
copolymer S
= 1/2
Example 4 cilostazol/ amorphous still still still
methacrylic acid amorphous amorphous amorphous
copolymer S
= 1/3
Example 5 cilostazol/ amorphous still still still
methacrylic acid amorphous amorphous amorphous
copolymer L
= 1/2
Comparative cilostazol/ amorphous crystal crystal crystall-
Example 1 methacrylic acid peak peak ized
copolymer S/ exists increases
polyethylene-
glycol - 1/1/0.2
Comparative cilostazol/ amorphous crystall- crystall- crystall-
Example 2 hypromellose ized ized ized
acetate
succinate - 1/1
Comparative cilostazol/ amorphous crystall- crystall- crystall-
Example 3 hypromellose ized ized ized
acetate
succinate - 1/2
[0057]
Each of the spray-dried powders prepared in the above
Comparative Examples 4 to 9 was measured about their powder
X-ray diffraction patterns.
Separately, about 2 g of each spray-dried powder
prepared in Comparative Examples 4 to 9 was put in a sample
CA 2899389 2019-02-01
36
tube. To the sample tube was added about 30 mL of purified
water to prepare a suspension, and the suspension was
shaken at 37 C for 1 hour. After shaking, the suspended
sample was got out of the sample tube, the excess water was
removed from the suspended sample, and then the powder X-
ray diffraction pattern thereof was measured to evaluate
the change of the crystalline property.
The results of the measure about the powder X-ray
diffraction are shown in Table 2 below. The solid
dispersion comprising a polymer and cilostazol which was
prepared by the spray drying method was quickly
crystallized shortly after suspended in water. Comparative
Examples 4 and 5 were crystallized only 1 hour after
suspended in water, and Comparative Example 6 was slightly
crystallized. Comparative Examples 7, 8, and 9 were
crystallized shortly after suspensions thereof were
prepared.
[Table 2]
Formulae Shortly after 37 C/1hr
preparation
Comparative cilostazol/hypromellose amorphous crystallized
Example 4 phthalate - 1/2
Comparative cilostazol/hypromellose acetate amorphous crystallized
Example 5 succinate = 1/2
Comparative cilostazol/methacrylic acid amorphous slightly
Example 6 copolymer S = 1/2 crystallized
Comparative cilostazol/hydroxypropyl- crystal peak crystallized
Example 7 cellulose = 1/2 exists (shortly after
suspended)
Comparative cilostazol/hypromellose = 1/2 amorphous crystallized
Example 8 (shortly after
_suspended)
Comparative cilostazol/polyvinylpyrrolidone amorphous crystallized
Example 9 K25 - 1/2 (shortly after
suspended)
CA 2899389 2019-02-01
37
[0058]
Test 2
The dissolution property of cilostazol from the solid
dispersion prepared in Example 3 which is a fine particle
(<150 pm) was evaluated by the dissolution test with the
following 6 test solvents.
1) 0.3 % Aqueous sodium lauryl sulfate (0.30 % SLS).
2) lot Fluid (pH 1.2) for disintegration test defined in
the Japanese Pharmacopoeia, containing 0.2 % sodium lauryl
sulfate.
3) McIlvaine buffer (pH 5.0) containing 0.2 % sodium lauryl
sulfate.
4) McIlvaine buffer (pH 6.8).
5) McIlvaine buffer (pH 6.8) containing 0.2 % sodium lauryl
sulfate.
6) McIlvaine buffer (pH 7.4).
[0059]
The dissolution test was carried out according to the
Japanese Pharmacopoeia, Dissolution Test, Apparatus 2
(Paddle Method). The test sample was prepared by mixing
the solid dispersion containing 100 mg of cilostazol with
lactose to increase the total weight 5 times that of the
solid dispersion. In the test, a sinker was not used and
the rotary speed of the paddle was 100 rpm. The solutions
taken in every sampling time were analyzed with a
CA 2899389 2019-02-01
38
spectrophotometer (UV 1200, SHIMADZU CORPORATION) to
measure the concentration of cilostazol in each sampling
solution.
The result was shown in Fig. 4.
Little cilostazol was dissolved out of the test sample
in water (0.3 % SLS), pH 1.2 McIlvaine buffer (+ 0.2 % SLS)
or pH 5.0 McIlvaine buffer (+ 0.2 % SLS). The result
of
the dissolution test using pH 6.8 McIlvaine buffer (+ 0.2 %
SLS) whose pH simulates the pH in lower gastrointestinal
tract showed a fast dissolution. Accordingly, when a
formulation of the present invention is administered to a
human, it is expected that cilostazol can be rapidly
dissolved out of the formulation to be released in its
lower gastrointestinal tract.
[0060]
Test 3
Using the same test method as Test 2 provided that the
test solvent is pH 7.4 McIlvaine buffer, the dissolution
character of cilostazol from the solid dispersion in a
neutral range was evaluated.
The test samples were as follows:
1) Jet-milled powder of crystalline cilostazol (milled with
a JM, Jet Mill (Spiral Jet Mill 50AS, Hosokawa Micron
Corporation), the same shall apply hereinafter).
CA 2899389 2019-02-01
39
2) Micronized powder (<150 pm) of the solid dispersion
prepared in Example 1.
3) Micronized powder (<150 pm) of the solid dispersion
prepared in Example 2.
4) Micronized powder (<150 pm) of the solid dispersion
prepared in Example 3.
[0061]
The result was shown in Fig. 5.
The dissolution of cilostazol in the solid dispersion
(Example 3, <150 pm) which was prepared from the mixture of
cilostazol and methacrylic acid copolymer S in a ratio of
1 : 2 by hot-melt extrusion was more than 5-fold faster
than that of the jet-milled powder of crystalline
cilostazol.
[0062]
Test 4
Using the same test method as Test 2 provided that the
test solvent is pH 7.4 McIlvaine buffer, the dissolution
character of cilostazol from the solid dispersion in a
neutral range was evaluated.
The test samples were as follows:
1) Jet-milled powder of crystalline cilostazol.
2) Micronized powder (<150 pm) of the solid dispersion
prepared in Example 3.
CA 2899389 2019-02-01
40
3) Micronized powder (250 to 500 pm) of the solid
dispersion prepared in Example 3.
[0063]
The result was shown in Fig. 6.
The result showed that the dissolution rate can be
controlled by adjusting the particle size of the micronized
solid dispersion.
[0064]
Formulation Example 1
Solid dispersion fine particle (<150 pm) 300 (parts by
of Example 3 weight)
Hypromellose (commercial name: METLOSE 50 (parts by
SR, grade: 90SH-4000SR, Shin-Etsu weight)
Chemical Co., Ltd.)
Light anhydrous silicic acid (adsolider 3 (parts by
101, Freund Corporation) weight)
Magnesium stearate (Taihei Chemical 1 (part by
Industrial Co., Ltd.) weight)
According to the above formula, the solid dispersion
fine particle, hypromellose, and light anhydrous silicic
acid were mixed in a polyethylene bag, and then magnesium
stearate was added thereto and further mixed. The mixed
powder was compressed with a rotary tablet press machine
(Clean Press, Kikusui Seisakusho Ltd.) equipped with
caplet-shaped (13.6 x 6.8 mm) dies and punches at a
tableting pressure of 1800 kg to prepare a caplet
containing 100 mg of cilostazol.
CA 2899389 2019-02-01
41
[0065]
Formulation Example 2
Solid dispersion fine particle (<150 pm) of 300 (parts
Example 3 by weight)
Hydroxypropylcellulose (commercial name: 50 (parts
NISSO HPC, grade: L, NIPPON SODA CO., LTD.) by weight)
Hydroxypropylcellulose (commercial name: 50 (parts
NISSO0 HPC, grade: M, NIPPON SODA CO., LTD.) by weight)
Light anhydrous silicic acid (adsolider 101, 3 (parts by
Freund Corporation) weight)
Magnesium stearate (Taihei
Chemical 1 (part by
Industrial Co., Ltd.) weight)
According to the above formula, the solid dispersion
fine particle, hydroxypropylcellulose, and light anhydrous
silicic acid were mixed in a polyethylene bag, and then
magnesium stearate was added thereto and further mixed.
The mixed powder was compressed with a rotary tablet press
machine (Clean Press, Kikusui Seisakusho Ltd.) equipped
with caplet-shaped (13.6 x 6.8 mm) dies and punches at a
tableting pressure of 1800 kg to prepare a caplet
containing 100 mg of cilostazol.
[0066]
Formulation Example 3
Solid dispersion fine particle (<500 pm) of 300 (parts
Example 3 _________________________________________ by weight)
Polyethylene oxide (commercial
name: 165 (parts
Polyox , grade: WSR-303, Dow Chemical) by weight)
Light anhydrous silicic acid (adsolider 201, 3 (parts by
Freund Corporation) weight)
Sodium stearyl fumarate (Rettenmaier Japan 1 (part by
Co., Ltd.) weight) ___
According to the above formula, the solid dispersion
fine particle, polyethylene oxide, and light anhydrous
CA 2899389 2019-02-01
42
silicic acid were mixed in a polyethylene bag, and then
sodium stearyl fumarate was added thereto and further mixed.
The mixed powder was compressed with a rotary tablet press
machine (Clean Press, Kikusui Seisakusho Ltd.) equipped
with caplet-shaped (13.6 x 6.8 mm) dies and punches at a
tableting pressure of 1800 kg to prepare a caplet
containing 100 mg of cilostazol.
[0067]
Formulation Example 4
Solid dispersion fine particle (<710 pm) of 300 (parts
Example 3 by weight)
Polyethylene oxide (commercial name: 165 (parts
Polyox , grade: WSR-303, Dow Chemical) by weight)
Light anhydrous silicic acid (adsolider 3 (parts by
101, Freund Corporation) weight)
Sodium stearyl fumarate (Rettenmaier Japan 1 (part by
Co., Ltd.) weight)
According to the above formula, the solid dispersion
fine particle, polyethylene oxide, and light anhydrous
silicic acid were mixed in a polyethylene bag, and then
sodium stearyl fumarate was added thereto and further mixed.
The mixed powder was compressed with a rotary tablet press
machine (Clean Press, Kikusui Seisakusho Ltd.) equipped
with caplet-shaped (13.6 x 6.8 mm) dies and punches at a
tableting pressure of 1800 kg to prepare a caplet
containing 100 mg of cilostazol.
CA 2899389 2019-02-01
43
[0068]
Formulation Example 5
Solid dispersion fine particle (<500 pm) of 300 (parts
Example 3 by weight)
Polyethylene oxide (commercial name: 165 (parts
PolymO, grade: WSR-303, Dow Chemical) by weight)
Light anhydrous silicic acid (adsolider 3 (parts by
101, Freund Corporation) weight)
Magnesium stearate (Taihei Chemical 1
(part by
Industrial Co., Ltd.) weight)
According to the above formula, the solid dispersion
fine particle, polyethylene oxide, and light anhydrous
silicic acid were mixed in a polyethylene bag, and then
magnesium stearate was added thereto and further mixed.
The mixed powder was compressed with a rotary tablet press
machine (Clean Press, Kikusui Seisakusho Ltd.) equipped
with caplet-shaped (13.6 x 6.8 mm) dies and punches at a
tableting pressure of 1800 kg to prepare a caplet
containing 100 mg of cilostazol.
[0069]
Formulation Example 6
First Layer
Solid dispersion fine particle (<500 )1m) 225 (parts by
of Example 3 weight)
Polyethylene oxide (Polyox WSR-303, Dow 100 (parts by
Chemical) weight)
Polyethylene glycol 6000 (Sanyo Chemical 10 (parts by
Industries, Ltd.) weight)
Light anhydrous silicic acid (Adsolider 3 (parts by
101, Freund Corporation) weight)
Magnesium stearate (Taihei Chemical 1
(part by
Industrial Co., Ltd.) weight)
CA 2899389 2019-02-01
44
Second Layer
Cilostazol (hammer-milled 25 (parts by weight)
product, mean particle size:
about 20 pm)
Microcrystalline cellulose 15.5 (parts by weight)
(Ceolus pH101, Asahi Kasei
Chemicals Corporation)
Low substituted hydroxypropyl- 5 (parts by weight)
cellulose (commercial name: L-
HPC , grade: LH-11, Shin-Etsu
Chemical Co., Ltd.)
Hydroxypropylcellulose 4 (parts by weight)
(commercial name: NISSO HPC, wherein "2" was added
grade: L, NIPPON SODA CO., LTD.) as a powder, the other
"2" was added as a
binding solution.
Magnesium stearate (Taihei 0.5 (parts by weight)
Chemical Industrial Co., Ltd.)
To prepare a powder for the first layer, the solid
dispersion fine particle, polyethylene oxide, polyethylene-
glycol 6000, and light anhydrous silicic acid were mixed in
a drum mixer, then magnesium stearate was added thereto,
and further mixed. To prepare a granule for the second
layer, cilostazol, microcrystalline cellulose, low
substituted hydroxypropylcellulose, and hydroxypropyl-
cellulose (to be added as a powder) were put in a mixer
granulator (Kneader NSK-350SR, OKADA SEIKO C0_,LTD.), and
the mixture was kneaded/granulated with 10 % aqueous
hydroxypropylcellulose as a binding solution, dried in FLO-
COATER0 (FLO-5, Freund Corporation), and size-regulated
with Power Mill (P-35 type, Dalton Co.,Ltd.), and then
magnesium stearate was added thereto, and further mixed.
CA 2899389 2019-02-01
45
The tableting was carried out with a bi-layer
tableting machine (PICCOLA BI-LAYER, RIVA) equipped with
caplet-shaped (13.6 x 6.8 mm) dies and punches. The powder
for the first layer was put on the dies and weakly
compressed. Subsequently, the granule for the second layer
was put around the compressed product on the same dies and
compressed at a tableting pressure of about 2000 kg to
prepare a bi-layer tablet containing 100 mg of cilostazol.
[0070]
Formulation Example 7
First Layer
Solid dispersion fine particle (<500 pm) 225 (parts by
of Example 3 weight)
Polyethylene oxide (Polyox WSR-303, Dow 125 (parts by
Chemical) weight)
Hydroxypropylcellulose (commercial name: 20 (parts by
NISSO0 HPC, grade: SSL, NIPPON SODA CO., weight)
LTD.)
Light anhydrous silicic acid (adsolider 3 (parts by
101, Freund Corporation) weight)
Dibutylhydroxytoluene (Merck Ltd.) 0.5 (parts by
weight)
Sodium stearyl fumarate (Rettenmaier Japan 1.5 (parts by
Co., Ltd.) weight)
CA 2899389 2019-02-01
46
Second Layer
Cilostazol (hammer-milled 25 (parts by weight)
product, mean particle size about
20 pm)
Microcrystalline cellulose 15.5 (parts by weight)
(Ceolus pH101, Asahi Kasei
Chemicals Corporation)
Low substituted hydroxypropyl- 5 (parts by weight)
cellulose (commercial name: L-
RPC , grade: LH-11, Shin-Etsu
Chemical Co., Ltd.)
Hydroxypropylcellulose 4 (parts by weight)
(commercial name: NISSO HPC, wherein "2" was added
grade: L, NIPPON SODA CO., LTD.) as a powder, the other
"2" was added as a
binding solution.
Magnesium stearate (Taihei 0.5 (parts by weight)
Chemical Industrial Co., Ltd.)
To prepare a powder for the first layer, the solid
dispersion fine particle, polyethylene
oxide,
hydroxypropylcellulose, dibutylhydroxytoluene, and light
anhydrous silicic acid were mixed in a drum mixer, then
sodium stearyl fumarate was added thereto, and further
mixed. To prepare a granule for the second layer,
cilostazol, microcrystalline cellulose, low substituted
hydroxypropylcellulose, and hydroxypropylcellulose (to be
added as a powder) were put in a mixer granulator (Kneader
NSK-350SR, OKADA SEIKO CO.,LTD.), and the mixture was
kneaded/granulated with 10 % aqueous hydroxypropylcellulose
as a binding solution, dried in FLO-COATER0 (FLO-5, Freund
Corporation), and size-regulated with Power Mill (P-3S type,
1
CA 2899389 2019-02-01
47
Dalton Co.,Ltd.), and then magnesium stearate was added
thereto, and further mixed.
The tableting was carried out with a bi-layer
tableting machine (PICCOLA BI-LAYER, RIVA) equipped with
caplet-shaped (13.6 x 6.8 mm) dies and punches. The powder
- for the first layer was put on the dies and weakly
compressed. Subsequently, the granule for the second layer
was put around the compressed product on the same dies and
compressed at a tableting pressure of about 2000 kg to
prepare a bi-layer tablet containing 100 mg of cilostazol.
[0071]
Formulation Example 8
Solid dispersion fine particle (<500 um) of 225 (parts
Example 3 by weight)
Polyethylene oxide (Polyox WSR-303, Dow 135 (parts
Chemical) by weight)
Hydroxypropylcellulose (commercial name: 20
(parts by
NISSO HPC, grade: SSL, NIPPON SODA CO., weight)
LTD.)
Light anhydrous silicic acid (adsolider 101, 3 (parts by
Freund Corporation) weight)
Dibutylhydroxytoluene (Merck Ltd.) 0.5 (parts
by weight)
Sodium stearyl fumarate (Rettenmaier Japan 1.5 (parts
Co., Ltd.) by weight)
According to the above formula, the solid dispersion
fine particle, polyethylene oxide, hydroxypropylcellulose,
dibutylhydroxytoluene, and light anhydrous silicic acid
were mixed in a drum mixer, and then sodium stearyl
fumarate was added thereto and further mixed. The mixed
powder was compressed with a rotary tablet press machine
CA 2899389 2019-02-01
48
(Clean Press, Kikusui Seisakusho Ltd.) equipped with
caplet-shaped (13.6 x 6.8 mm) dies and punches at a
tableting pressure of 1800 kg to prepare a caplet
containing 100 mg of cilostazol.
[0072]
Test 5: Administration of solid dispersion comprising
cilostazol to minipigs (Evaluation of the effect in vivo)
To minipigs (about 9 months old, body weight 15 -
24 kg, NIBS, Nisseiken Co., Ltd.) which were fed 1 hour
before, a gelatin capsule containing each of the solid
dispersions prepared in Examples 2 and 3, and Comparative
Example 3 was administered via a gavage, in which each
capsule contained 200 mg of cilostazol, i.e., 400 mg of the
solid dispersion for Example 2 and 600 mg of the solid
dispersion for Example 3 and Comparative Example 3.
Shortly after the administration, 50 mL of injectable water
was administered via a stomach tube to the minipigs.
The control sample was prepared by the same
administration with a cilostazol tablet (Product name:
Pletaal tablet) 100 mg.
The blood for the test was collected from a catheter
inserted into the large sinus cavity. The blood collection
was done at the time, before the administration; and 0.5, 1,
2, 3, 4, 6, 8, 12, 16 and 24 hours after the administration,
provided that the sampling of 16 hours after the
CA 2899389 2019-02-01
49
administration was skipped in the Pletaalo tablet test.
The amount of blood sampling was about 1.5 mL (n = 4). The
collected blood was centrifuged at 3000 rpm for 15 minutes
to give plasma thereof. The concentration of cilostazol in
the plasma was measured with LC-MS. Based on the profile
of the plasma concentration, maximum plasma concentration
(Cmax) and area under the plasma concentration curve (AUC),
maximum plasma drug concentration time (T.), and mean
residence time (MRTiast.) were calculated.
[0073]
The results of Test 5 are shown in Table 3 and Fig. 7.
The solid dispersions containing cilostazol of
Examples 2 and 3, in which methacrylic acid copolymer S was
used, exhibited higher improvement effect of the absorption
in C. and AUC, compared with Pletaal tablet. In addition,
both of Truax and MRTLast of Examples 2 and 3 were markedly
increased compared with Pletaal tablet, which indicated
improvement effect of the absorption in lower section of
the small intestine and in the large intestine.
According to the above results, it has become clear
that the solid dispersion which retains cilostazol in an
amorphous state with methacrylic acid copolymer is improved
on the absorption in lower section of the small intestine
and in the large intestine, with the improvement of the
solubility of cilostazol.
CA 2899389 2019-02-01
50
[Table 3]
Pletaal Example Example Comparative
tablet 2 3 Example 3
(ng/mL) 196.5 447.3 490.6 303.7
AUCan (ng.hr/mL) 1349.0 3848.9 - 3447.9
1870.7
T. (hr) 2.8 14.0 14.0 17.0
MRTiast (hr) 5.0 11.0 12.3 16.1
[0074]
Test 6: Administration of solid dispersion formulation
comprising cilostazol to dogs (Evaluation of the effect in
vivo)
To male beagle dogs (about 30 months old, body weight
8.0 - 12.0 kg, Nosan Beagle, NALK CORPORATION), the
hydrogel bi-layer tablet prepared in Formulation Example 6
was administered via a gavage. Shortly
after the
administration, 40 mL of 0.1 N aqueous hydrochloric acid
was administered via a gavage. 30 minutes
before the
administration, about 50 g of CD5 (Oriental Yeast Co.,
ltd.) was given to the dogs, then the dogs were fasted
until the last blood collection. As the
control sample,
Pletaal tablet 100 mg was used.
The blood collection was done at the time, before the
administration; and 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24
hours after the administration, provided that the samplings
of 12 and 24 hours after the administration were skipped in
the Pletaal tablet test. The amount of blood sampling was
about 1 mL (n - 6). The collected blood was centrifuged at
3000 rpm for 10 minutes to give serum thereof. The
CA 2899389 2019-02-01
51
concentration of cilostazol in the serum was measured with
LC-MS.
Based on the profile of the serum concentration,
maximum serum concentration (Cmax) and area under the serum
concentration curve (AUC), maximum serum drug concentration
time (Tmax), and mean residence time (MRTiaat) were
calculated.
The results of Test 6 are shown in Table 4 and Fig. 8.
[Table 4]
Pletaal Formulation
tablet Example 6
Cmax (ng/mL) 1561.4 1782.0
AUCt (ng.hr/mL) 5364.6 13544.3
Tmax (hr) 2.83 9.0
MRTIast (hr) 3.93 8.63
[0075]
Test 7: Administration of solid dispersion formulation
comprising cilostazol to dogs (Diet effect)
To male beagle dogs (about 30 months old, body weight
8.0 - 12.0 kg, Nosan Beagle, NALK CORPORATION), the solid
dispersion was administered via a gavage, and then the diet
effect was evaluated. To the solid dispersion prepared in
Example 3 (250 to 500 pm) which contains 100 mg of
cilostazol, the same weight of lactose was added to
increase the total weight twice. A capsule
for dog was
filled with the mixture and administered to the dogs.
Shortly after the administration, 40 mL of 0.1 N aqueous
hydrochloric acid was administered via a gavage.
CA 2899389 2019-02-01
52
For the fasting group, the dogs had been fasted from
18 hours before the administration to the last blood
collection.
For the feeding group, the dogs were given about 50 g
of CD5 (Oriental Yeast Co., ltd.) 30 minutes before the
administration, then the dogs had been fasted until the
last blood collection.
The blood collection was done at the time, before the
administration; and 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24
hours after the administration. The amount of blood
sampling was about 1 mL (n = 6). The collected blood was
centrifuged at 3000 rpm for 10 minutes to give serum
thereof. The concentration of cilostazol in the serum was
measured with LC-MS.
Based on the profile of the serum concentration,
maximum serum concentration (Cma.) and area under the serum
concentration curve (AUC), maximum plasma .drug
concentration time (Tma.), and mean residence time (MRTiast)
were calculated.
The results of Test 7 are shown in Table 3.
[Table 5]
Fasting Feeding
Cmax (ng/mL) 1930.3 1466.0
AUCt (ng.hr/mL) 4779.3 6300.3
Tmax (hr) 3.5 6.3
MRT]..st (hr) 4.0 6.3
CA 2899389 2019-02-01
53
[0076]
Test 8
The dissolution character of cilostazol from the
tablets prepared in Formulation Examples 6, 7 and 8, and
Pletaal tablet 100 mg was evaluated.
The dissolution test was carried out according to the
Japanese Pharmacopoeia, Dissolution Test, Apparatus 2
(Paddle Method) wherein the test solvent was pE 6.8
phosphate buffer containing 0.3 % cetyltrimethylammonium
bromide. In the test, a sinker was used and the rotary
speed of the paddle was 150 rpm. The solutions taken in
every sampling time were analyzed with a spectrophotometer
(UV 1200, SHIMADZU CORPORATION) to measure the
concentration of cilostazol in each sampling solution.
[0077]
The result was shown in Fig. 9.
The result showed that the tablets of Formulation
Examples 6, 7 and 8 have a dissolution profile of suspended
release property, compared with that of Pletaal tablet
100 mg.
CA 2899389 2019-02-01
